Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT
Primary Purpose
Multiple Myeloma
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
allogeneic HSCT
Sponsored by

About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring Hematopoietic Stem Cell Transplantation, Multiple Myeloma
Eligibility Criteria
Inclusion Criteria:
- Multiple Myeloma stage II or III acc. to Salmon and Durie (chemosensitive or refractory) and relapse or progression after high dose chemotherapy with autologous stem cell support
- Age 18-60 years
- ECOG-performance status 0-1
- Availability of a HLA-compatible unrelated donor (HLA-A, -B, -DRB1, -DQB1)
Exclusion Criteria:
- Serious concomitant medical disease that would limit life span or ability to tolerate chemotherapy
- Severe cardiac failure (ejection fraction < 40%)
- Severe impairment of renal function (Creatinine clearance < 50ml/min)
- Severe impairment of liver function (bilirubine > 2 fold of upper limits of normal)
- Pregnant or lactating women
- Other major organ or system dysfunctions(GI, neurological, psychiatric dysfunctions that would impair tolerance of chemotherapy or prolonged haematological recovery)
- Positivity for HIV
Sites / Locations
- University Medical Center Hamburg-Eppendorf
Outcomes
Primary Outcome Measures
Engraftment, chimerism, toxicity, non-relapse mortality
Secondary Outcome Measures
Evaluation of response/GvHD/ infectious complications/ disease-free survival, Prognostic impact of cytogenetic, Evaluation of incidence and prognostic impact of molecular remission in patients with clinically complete remission.
Full Information
NCT ID
NCT00599495
First Posted
January 11, 2008
Last Updated
September 1, 2022
Sponsor
Universitätsklinikum Hamburg-Eppendorf
1. Study Identification
Unique Protocol Identification Number
NCT00599495
Brief Title
Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT
Official Title
Allogeneic Stem Cell Transplantation From Unrelated Donors After Dose-reduced Intensity Conditioning Regimen for Patients With Multiple Myeloma and Relapse After Autologous Stem Cell Transplantation: A Phase II-study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
November 2002 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitätsklinikum Hamburg-Eppendorf
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether a reduced intensity conditioning regimen followed by allogeneic stem cell transplantation from unrelated donors is a feasible and effective treatment for patients with multiple myeloma who failed a previous autologous stem cell transplantation.
Detailed Description
The purpose of this study is to determine whether a reduced intensity conditioning regimen followed by allogeneic stem cell transplantation from unrelated donors is a feasible and effective treatment for patients with multiple myeloma who failed a previous autologous stem cell transplantation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma
Keywords
Hematopoietic Stem Cell Transplantation, Multiple Myeloma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
allogeneic HSCT
Intervention Description
dose-reduced conditioning regimen
Primary Outcome Measure Information:
Title
Engraftment, chimerism, toxicity, non-relapse mortality
Time Frame
Follow-up until day +1095
Secondary Outcome Measure Information:
Title
Evaluation of response/GvHD/ infectious complications/ disease-free survival, Prognostic impact of cytogenetic, Evaluation of incidence and prognostic impact of molecular remission in patients with clinically complete remission.
Time Frame
Follow-up until day +1095
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Multiple Myeloma stage II or III acc. to Salmon and Durie (chemosensitive or refractory) and relapse or progression after high dose chemotherapy with autologous stem cell support
Age 18-60 years
ECOG-performance status 0-1
Availability of a HLA-compatible unrelated donor (HLA-A, -B, -DRB1, -DQB1)
Exclusion Criteria:
Serious concomitant medical disease that would limit life span or ability to tolerate chemotherapy
Severe cardiac failure (ejection fraction < 40%)
Severe impairment of renal function (Creatinine clearance < 50ml/min)
Severe impairment of liver function (bilirubine > 2 fold of upper limits of normal)
Pregnant or lactating women
Other major organ or system dysfunctions(GI, neurological, psychiatric dysfunctions that would impair tolerance of chemotherapy or prolonged haematological recovery)
Positivity for HIV
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicolaus Kroeger, Prof. Dr.
Organizational Affiliation
Universitätsklinikum Hamburg-Eppendorf
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medical Center Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
19912215
Citation
Kroger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhauser M, Nagler A, Zander AR, Heinzelmann M, Brand R, Gahrton G, Morris C, Niederwieser D, de Witte T. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol. 2010 Jan;148(2):323-31. doi: 10.1111/j.1365-2141.2009.07984.x. Epub 2009 Nov 12.
Results Reference
result
Learn more about this trial
Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT
We'll reach out to this number within 24 hrs